This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Neomycin

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Neomycin is an antibiotic that is indicated for:

  • bowel sterilisation prior to surgery - too toxic for parenteral administration

N.B. Small amounts may be absorbed by patients with hepatic impairment and ototoxicity may result, especially if there is concomitant uraemia.

Cautions:

  • increase dose interval in renal impairment. Also, if the impairment is severe, the dose should be reduced.
  • beware drug interactions - see current issue of BNF

Contra-indications:

  • pregnancy
  • myasthenia Gravis - aminoglycosides may impair neuromuscular transmission; indeed large doses given during surgery may be responsible for a transient myasthenic syndrome

Side-effects:

  • vestibular damage
  • reversible nephrotoxicity

N.B. Both vestibular and renal toxicity are dose related and occur most often in the elderly and in those with renal impairment.

  • hypomagnesaemia in prolonged therapy
  • pseudomembranous colitis

Route of administration;

  • Oral: - tablets - elixir

The summary of product characteristics should be consulted before prescribing this drug.


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.